Major shareholder announcement - Pharma Equity Group A/S
| Major shareholder announcement - Pharma Equity Group A/S | |
23 April 2024 Company Announcement no. 14 Pharma Equity Group A/S has, in accordance with section 38 of the Capital Markets Act, received major shareholder notification, that DMZ Holding ApS has acquired shares in Pharma Equity Group A/S. As a result, DMZ Holding ApS has increased their ownership stake to over 5% in Pharma Equity Group A/S. For further information, please contact: | |
| Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114 Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222 | |
About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects. The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth. |
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Bulletin from BTS Group AB's Annual General Meeting3.5.2024 17:34:40 CEST | Press release
Stockholm May 3, 2024 The Annual General Meeting approved the proposed dividend to shareholders of SEK 5,70 per share, divided into two payment occasions of SEK 2,85 each. The record date for the first payment of SEK 2,85 was determined to Tuesday May 7, 2024 and for the second payment of SEK 2,85 was determined to Wednesday November 13, 2024. The first payment is expected to be made on Monday May 13, 2024 and the second payment is expected to be made on Monday November 18, 2024. The Annual General Meeting discharged the members of the Board of Directors and the CEO from liability for the financial year 2023 and approved the remuneration report for 2023 prepared by the Board of Directors. The Annual General Meeting approved the remuneration to board members to a total of SEK 1,735,000, of which SEK 525,000 to the Chairman and SEK 235,000 to each of the other board members, and SEK 60,000 to the Deputy Board member. A total fee of SEK 225,000 shall be paid for committee work. Mariana Bu
Kommuniké från BTS Group ABs årsstämma3.5.2024 17:34:40 CEST | Pressemelding
Stockholm 3 maj 2024 Årsstämman fastställde föreslagen utdelning till aktieägarna om 5,70 kronor per aktie, uppdelat på två utbetalningstillfällen om vardera 2,85 SEK. Som avstämningsdag för den första utbetalningen om 2,85 SEK fastställdes tisdagen den 7 maj 2024 och för den andra utbetalningen om 2,85 SEK fastställdes onsdagen den 13 november 2024. Den första utbetalningen beräknas ske måndagen den 13 maj 2024 och den andra utbetalningen beräknas ske måndagen den 18 november 2024. Årsstämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för verksamhetsåret 2023 samt godkände den av styrelsen upprättade ersättningsrapporten för 2023. Årsstämman fastställde arvodet till styrelseledamöter till totalt 1 735 000 kronor, varav 525 000 kronor till ordföranden och 235 000 kronor till respektive övrig styrelseledamot, samt 60 000 kronor till styrelsesuppleanten. För utskottsarbete skall ett totalt arvode om 225 000 kronor utgå. Mariana Burenstam Linder, Stefan Garde
Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer3.5.2024 17:32:16 CEST | Press release
Wistar’s Veglia lab identified how glioblastoma evades the immune system by inducing pro-tumor macrophages via a glucose based epigenetic modification. PHILADELPHIA, PA, May 03, 2024 (GLOBE NEWSWIRE) -- The Wistar Instituteassistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma — a serious and often fatal brain cancer — suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses. The lab’s discovery was published in the paper, “Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma,” in the journal Immunity. “Our study shows that the cellular mechanisms of cancer’s self-preservation, when sufficiently understood, can be used against the disease very effectively,” said Dr. Veglia. “I look forward to future research on metabolism-driven mechanisms of immunosuppression in glioblastoma, and I’m hopeful for all that we will continue to learn about
EIB submits Annual Financial Report 2023 on Form 18-K3.5.2024 17:12:55 CEST | Press release
3 May 2024 The EIB submits SEC Form 18-K The European Investment Bank (EIB) has submitted its SEC Form 18-K. To view the document, please go to: EDGAR Filing Documents for 0001104659-24-056727 (sec.gov). The 18-K has also been posted on the EIB website: EIB annual 18-K report 2023 ENDS
Camposol Holding PLC’s Invitation to the First Quarter 2024 Financial Results Presentation3.5.2024 17:00:00 CEST | Press release
Camposol Holding PLC will announce its financial results for the first quarter of 2024 on Monday, May 27, 2024, at 9:00 am Peru Time. In connection with this release, Jose Antonio Gomez-Bazan, CEO, Ricardo Naranjo Fernandez, CFO, and Jossue Yesquen Lihim, IRO, will host a conference call presentation and Q&A session. To register and participate in the conference call please use the following link: https://register.vevent.com/register/BIf823c18bd17a451f9db6353bf30a1b12 Participants are advised to log in to the conference call service and check their settings a few minutes before the conference call begins. To access the webcast presentation associated with the conference call, please use the following link: https://edge.media-server.com/mmc/p/xcv3cq9w If you are unable to participate in the conference call, a playback of the conference will be available until May 27, 2025. For further information, please contact: Jossue Yesquen Lihim, IRO Email: jyesquen@camposol.com About CAMPOSOL CAMP